EUVIMEDEUVIMED entdecken
Open Access

Costs of Drug Development and Research and Development Intensity in the US, 2000-2018

Aylin Sertkaya, Trinidad Beleche, Amber Jessup, Benjamin D Sommers

JAMA Network Open · 28.06.2024 · 7 (6) · e2415445

DOI: 10.1001/jamanetworkopen.2024.15445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 28.06.2024. Verfasst von Aylin Sertkaya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Eastern Research Group, Inc, Lexington, Massachusetts. Hauptthemen laut MEDLINE: Drug Development. Die Arbeit wurde bisher 270-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Understanding the cost of drug development can help inform the development of policies to reduce costs, encourage innovation, and improve patient access to drugs.

Objective

To estimate the cost of drug development by therapeutic class and trends in pharmaceutical research and development (R&D) intensity over time. Design, Setting, and Participants In this economic evaluation study, an analytical model of drug development constructed using public and proprietary sources that collectively cover data from 2000 to 2018 was used to estimate the cost of bringing a drug to market, overall and for specific therapeutic classes. The analysis for the study was completed in October 2020. Main Outcomes and Measures Three measures of development cost from nonclinical through postmarketing stages were estimated: mean out-of-pocket cost or cash outlay, mean expected cost, and mean expected capitalized cost. Pharmaceutical R&D intensity, defined as the ratio of R&D spending to total sales, from 2008 to 2019, based on the time frame for available data, was also analyzed.

Results

The estimated mean cost of developing a new drug was approximately $172.7 million (2018 dollars) (range, $72.5 million for genitourinary to $297.2 million for pain and anesthesia), inclusive of postmarketing studies. The cost increased to $515.8 million when cost of failures was included. When the costs of failures and capital were included, the mean expected capitalized cost of drug development increased to $879.3 million (range, $378.7 million for anti-infectives to $1756.2 million for pain and anesthesia); results varied widely by therapeutic class. The pharmaceutical industry as a whole experienced a decline of 15.6% in sales but increased R&D intensity from 11.9% to 17.7% from 2008 to 2019. By contrast, R&D intensity of large pharmaceutical companies increased from 16.6% to 19.3%, whereas sales increased by 10.0% (from $380.0 to $418.0 billion) over the same 2008 to 2019 period, even though the cost of drug development remained relatively stable or may have even decreased. Conclusions and Relevance In this economic evaluation of new drug development costs, even though the cost of drug development appears to have remained stable, R&D intensity of large pharmaceutical companies remained relatively unchanged, despite substantial growth in revenues during this period. These findings can inform the design of drug-related policies and their potential impacts on innovation and competition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentUnited StatesHumansDrug CostsDrug IndustryPharmaceutical Research

Autor:innen und Institutionen

  • Eastern Research Group, Inc, Lexington, Massachusetts.
  • Office of the Assistant Secretary for Planning and Evaluation, Office of Science and Data Policy, US Department of Health and Human Services, Washington, DC.
  • Now with Office of Inspector General, US Department of Health and Human Services, Washington, DC.
  • US Department of Health and Human Services, Washington, DC.
  • Now with Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Zitieren

APA

Sertkaya, A., Beleche, T., Jessup, A., & Sommers, B. D. (2024). Costs of Drug Development and Research and Development Intensity in the US, 2000-2018. JAMA Network Open, 7(6), e2415445. https://doi.org/10.1001/jamanetworkopen.2024.15445

Vancouver

Sertkaya A, Beleche T, Jessup A, Sommers BD. Costs of Drug Development and Research and Development Intensity in the US, 2000-2018. JAMA Network Open. 2024;7(6):e2415445. doi:10.1001/jamanetworkopen.2024.15445

BibTeX
@article{Sertkaya2024,
  author = {Sertkaya, Aylin and Beleche, Trinidad and Jessup, Amber and Sommers, Benjamin D},
  title = {Costs of Drug Development and Research and Development Intensity in the US, 2000-2018},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {6},
  pages = {e2415445},
  doi = {10.1001/jamanetworkopen.2024.15445}
}
Kostenlos starten →